MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida. Show more
Location: 1200 Brickell Avenue, Miami, FL, 32183, United States | Website: https://mirapharmaceuticals.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
26.51M
52 Wk Range
$0.73 - $2.56
Previous Close
$1.39
Open
$1.40
Volume
144,293
Day Range
$1.35 - $1.40
Enterprise Value
22.79M
Cash
730.5K
Avg Qtr Burn
-1.519M
Insider Ownership
22.04%
Institutional Own.
5.06%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ketamir-2 Details Neuropathic pain | Phase 2a Initiation |